or Try an Advanced Search...

    Technical Analysis for SNDX - Syndax Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    C 21.06 2.38% 0.49
    SNDX closed up 2.38 percent on Friday, April 26, 2024, on 71 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 6
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Up
    Historical SNDX trend table...
    Date Alert Name Type % Chg
    Slingshot Bearish Bearish Swing Setup 0.00%
    Stochastic Buy Signal Bullish 0.00%
    Oversold Stochastic Weakness 0.00%
    Gapped Down Weakness 2.38%
    Oversold Stochastic Weakness 2.38%
    Oversold Stochastic Weakness 1.30%
    Up 3 Days in a Row Strength 0.43%
    Oversold Stochastic Weakness 0.43%
    Slingshot Bearish Bearish Swing Setup 0.48%
    Oversold Stochastic Weakness 0.48%
    Older End-of-Day Signals for SNDX ...

       Recent Intraday Alerts

    Alert Time
    Up 3% about 11 hours ago
    60 Minute Opening Range Breakout about 12 hours ago
    Up 2% about 14 hours ago
    Rose Above 10 DMA about 14 hours ago
    Rose Above Previous Day's High about 17 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    SNDX Chart by TradingView
    Basic chart:

    Profile

    Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company's lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Waltham, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Clinical Medicine Solid Tumors Breast Cancer Antineoplastic Drugs Treatment Of Breast Cancer Cancer Cell Lung Cancer Cancer Therapies Hematological Malignancies Pyridines National Cancer Institute Benzamides Histone Deacetylase Inhibitor

    Is SNDX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 10 Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
    Apr 8 Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
    Apr 5 Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    Apr 3 Crinetics, Syndax gain amid pitch at Sohn charity conference (update)
    Mar 28 Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
    Mar 28 Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope
    Mar 28 Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
    Mar 26 FDA grants priority review for Syndax leukemia drug, sets action date
    Mar 26 Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
    Mar 18 Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
    See more SNDX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 25.34
    52 Week Low 11.23
    Average Volume 1,085,291
    200-Day Moving Average 19.07
    50-Day Moving Average 22.64
    20-Day Moving Average 21.88
    10-Day Moving Average 20.93
    Average True Range 0.84
    RSI (14) 43.18
    ADX 14.25
    +DI 18.39
    -DI 23.77
    Chandelier Exit (Long, 3 ATRs) 21.85
    Chandelier Exit (Short, 3 ATRs) 22.65
    Upper Bollinger Bands 24.03
    Lower Bollinger Band 19.72
    Percent B (%b) 0.31
    BandWidth 19.71
    MACD Line -0.56
    MACD Signal Line -0.47
    MACD Histogram -0.0848
    Fundamentals Value
    Market Cap 1.79 Billion
    Num Shares 84.8 Million
    EPS -2.59
    Price-to-Earnings (P/E) Ratio -8.13
    Price-to-Sales 12.67
    Price-to-Book 5.22
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 22.20
    Resistance 3 (R3) 22.13 21.68 22.01
    Resistance 2 (R2) 21.68 21.39 21.72 21.95
    Resistance 1 (R1) 21.37 21.21 21.53 21.44 21.88
    Pivot Point 20.92 20.92 21.00 20.96 20.92
    Support 1 (S1) 20.61 20.63 20.77 20.68 20.24
    Support 2 (S2) 20.16 20.45 20.20 20.17
    Support 3 (S3) 19.85 20.16 20.11
    Support 4 (S4) 19.92